Meta Platforms Inc vs GeneDx Holdings Corp — how do they compare? Meta Platforms Inc trades at $600.78 (market cap $1.53T), while GeneDx Holdings Corp trades at $82 (market cap $2.44B). The key difference: Meta Platforms Inc is far larger — about 627× GeneDx Holdings Corp's market cap, and Meta Platforms Inc pays a 0.35% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| META | WGS | |
|---|---|---|
Market Cap | $1.53T | $2.44B |
Volume | 24,093,972 | — |
Sector | Media | Technology |
52-Week High | $790.00 | $167.51 |
52-Week Low | $525.72 | $34.51 |
Enterprise Value | $1.55T | $2.48B |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
META trades at $594.92, up 0.48% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations ($10.44 vs $6.70), though Q2 2026 missed. Technical indicators show bearish momentum with RSI at 96.23 suggesting overbought conditions. The company launched Muse Spark AI model and faces ongoing legal challenges regarding youth addiction lawsuits.
Outlook remains positive with analyst consensus price target of $761.95 (28% upside) and 79% buy ratings. Key risks include regulatory lawsuits, aggressive AI capex spending ($102B in 2025), and competitive pressures. Revenue growth continues at 22% year-over-year to $201B, supporting long-term investment thesis despite near-term technical weakness.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →